Genmab — April 2020

[E_L]

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab https://www.nature.com/articles/s41375-020-0840-y

[Sukkeralf]

We already have seen Farydak (panobinostat) - a pan HDAC inihibitor approved for MM. I dont think Novartis ever made trials with daratumumab even though panobinostat also upregulates CD38. Tox issues with HDAC are heavy if I remember correctly

[E_L]

do you happen to know if JNJ owns such an inhibitor?

[Sukkeralf]

but maybe its a different story with a selective HDAC6 inhibitor - so lets give ricolinostat a warm welcome in combination with daratumumab :-)'

[Sukkeralf]

I dont think so

[E_L]

[Sukkeralf]

Its seems like Celgene bought Acetylon Pharmaceuticals and outsourced ricolinostat to Regenacy Pharmaceuticals

[Sukkeralf]

So I guess we will not see anything from that - nice papers but no commercial value

[GeorgeBest]

Webinar https://twitter.com/genmab/status/1255519832063258624?s=21

[E_L]

ASCO titels up https://meetinglibrary.asco.org/results/Epcoritamab ?meetingView=2020 ASCO Virtual Scientific Program&page=1

[E_L]

Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or...

[E_L]

Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with...

[E_L]

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific...

[E_L]

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20...

[E_L]

and 7 results
for Dara

[GeorgeBest]

Thanks E L, så usual you were the fastest

[GeorgeBest]

as usual

[JørgenVarnæs]

Nice. Could be grelt
Winther another run at the throne in cll

[JørgenVarnæs]

iPad

[Solsen]

Nu skal jeg til at have noter til alle de vanskelige navne